What should I pay attention to if I have fatty liver disease?

Fatty liver disease—also known as hepatic steatosis—refers to the accumulation of excess fat in liver cells. It is broadly categorized into two main types: nonalcoholic fatty liver disease (NAFLD), which is not related to significant alcohol use, and alcoholic fatty liver disease (AFLD), caused by heavy or prolonged alcohol consumption. NAFLD itself spans a spectrum from simple steatosis (benign fat accumulation) to nonalcoholic steatohepatitis (NASH), which involves inflammation and hepatocyte injury and may progress to fibrosis, cirrhosis, or even hepatocellular carcinoma.

Key lifestyle and medical considerations include maintaining a healthy weight through gradual, sustainable weight loss—ideally 3% to 5% of body weight for metabolic benefit, and up to 7% to 10% for meaningful improvement in liver histology. A balanced, nutrient-dense diet—such as the Mediterranean diet—is strongly recommended, emphasizing whole grains, legumes, fruits, vegetables, lean proteins, and unsaturated fats while limiting added sugars, refined carbohydrates, saturated fats, and ultra-processed foods. Regular physical activity—aiming for at least 150 minutes per week of moderate-intensity aerobic exercise—is essential for improving insulin sensitivity and reducing hepatic fat content.

Alcohol intake should be strictly limited or avoided entirely, particularly in individuals with NAFLD, as even modest alcohol consumption may exacerbate liver injury and accelerate disease progression. Routine screening and management of comorbidities—including type 2 diabetes, hypertension, dyslipidemia, and obstructive sleep apnea—are critical, given their strong bidirectional relationship with fatty liver disease. Patients should avoid unnecessary medications, supplements, or herbal products with known hepatotoxic potential unless prescribed and monitored by a healthcare provider.

Regular follow-up with a primary care physician or hepatologist is advised to monitor liver enzyme trends (ALT, AST), assess metabolic parameters, and determine if further evaluation—such as transient elastography (FibroScan®), MRI-based proton density fat fraction (PDFF), or, in select cases, liver biopsy—is warranted. Early detection and consistent, evidence-based interventions significantly reduce the risk of advanced liver disease and improve long-term outcomes.